FDAnews Device Daily Bulletin
Medical Devices / Submissions and Approvals

Intrinsic Therapeutics Receives PMA for Spinal Implant

Feb. 14, 2019

The FDA granted Intrinsic Therapeutics’ premarket approval for its Barricaid anular closure device for reducing reherniation following the removal of a herniated disc.

The device is intended for skeletally mature patients with a pinched nerve, with or without back pain, from a posterior or posterolateral hernia.

The Barricaid device consists of a woven polyester occlusion component that is attached to the adjacent vertebral body with a titanium bone anchor.

View today's stories